#pharmaceuticalregulations

2026 is bringing major regulatory changes across pharmaceuticals, medical devices, and cosmetics.

From evolving EU pharmaceutical legislation and FDA guidance to MoCRA enforcement and medical device cybersecurity, staying ahead is more important than ever.

Explore the key regulatory updates shaping 2026 and what they mean for your compliance strategy.

Freyr supports pharmaceutical manufacturers with drug registration in China by guiding them through the full NMPA process. Our services include product classification, registration documentation, and approval support to ensure smooth compliance with China's regulatory standards.

The Central Drugs Standard and Control Organisation (CDSCO) is India’s foremost regulatory authority for overseeing Cosmetics, Pharmaceuticals, and Medical Devices. It wields significant influence within the country and operates under the Directorate General of Health Services, Ministry of Family Welfare & Health, and the Government of India.

To enhance regulatory oversight, the Indian Government has disclosed its intention to subject all medical devices, including implants and contraceptives, to CDSCO’s scrutiny. Additionally, CDSCO collaborates with state regulators to issue licenses for specific specialized categories of critical drugs, such as Blood and Blood Products, I.V. fluids, Vaccines, and Sera.